Related Experiment Videos
Prostate-specific antigen levels and subsequent prostate cancer: potential for screening
K J Helzlsouer1, J Newby, G W Comstock
1Department of Epidemiology, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205.
Summary
Elevated prostate-specific antigen (PSA) levels in blood predict future prostate cancer development. Higher PSA concentrations were observed up to six years before diagnosis, indicating PSA
Area of Science:
- Urology
- Oncology
- Biomarker Research
Background:
- Prostate-specific antigen (PSA) is a known marker for prostatic diseases, including prostate cancer.
- PSA levels are clinically utilized for monitoring prostate cancer treatment response.
- Current detection methods for prostate cancer often involve PSA in conjunction with digital rectal examination or ultrasonography.
Purpose of the Study:
- To investigate the association between baseline serum PSA levels and the subsequent diagnosis of prostate cancer.
- To determine if PSA levels can serve as an early indicator for prostate cancer development.
Main Methods:
- Serum samples from 35 men who later developed prostate cancer and 35 matched controls were analyzed.
- Blood samples were collected in 1974 from a community-based serum bank.
- PSA levels were measured and compared between cases and controls over a follow-up period.
Main Results:
- Significantly higher serum PSA levels were found in men who subsequently developed prostate cancer, up to 6 years prior to diagnosis.
- PSA levels decreased as the time to diagnosis increased.
- For cases diagnosed within 3 years, mean PSA was 16.2 µg/L vs. 2.4 µg/L for controls (P=0.002); for years 4-6, mean PSA was 9.6 µg/L vs. 1.3 µg/L (P=0.0002).
Conclusions:
- Elevated serum PSA levels are predictive of subsequent prostate cancer diagnosis.
- PSA testing shows potential as an early detection biomarker for prostate cancer.
- The predictive value of PSA for prostate cancer detection is demonstrated years before clinical diagnosis.